Economic Times | US FDA deems Novartis' heart failure candidate a 'breakthrough' PMLiVE The US Food and Drug Administration (FDA) has recognised that Novartis' serelaxin could be an important step change in acute heart failure (AHF) therapy by granting it 'breakthrough' status. Anticipation has been growing about serelaxin (RLX030) in ... Novartis heart failure drug gets FDA incentives FDA grants Breakthrough Therapy designation to Novartis' serelaxin (RLX030 ... Novartis Heart-Failure Drug Wins 'Breakthrough' Status at FDA |
